Brown P D, Eshleman J S, Foote R L, Strome S E
Division of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):737-43. doi: 10.1016/s0360-3016(00)00721-5.
The effect of high-dose radiation therapy on facial nerve grafts is controversial. Some authors believe radiotherapy is so detrimental to the outcome of facial nerve graft function that dynamic or static slings should be performed instead of facial nerve grafts in all patients who are to receive postoperative radiation therapy. Unfortunately, the facial function achieved with dynamic and static slings is almost always inferior to that after facial nerve grafts. In this retrospective study, we compared facial nerve function in irradiated and unirradiated nerve grafts. METHODS AND MATERIALS The medical records of 818 patients with neoplasms involving the parotid gland who received treatment between 1974 and 1997 were reviewed, of whom 66 underwent facial nerve grafting. Fourteen patients who died or had a recurrence less than a year after their facial nerve graft were excluded. The median follow-up for the remaining 52 patients was 10.6 years. Cable nerve grafts were performed in 50 patients and direct anastomoses of the facial nerve in two. Facial nerve function was scored by means of the House-Brackmann (H-B) facial grading system. Twenty-eight of the 52 patients received postoperative radiotherapy. The median time from nerve grafting to start of radiotherapy was 5.1 weeks. The median and mean doses of radiation were 6000 and 6033 cGy, respectively, for the irradiated grafts. One patient received preoperative radiotherapy to a total dose of 5000 cGy in 25 fractions and underwent surgery 1 month after the completion of radiotherapy. This patient was placed, by convention, in the irradiated facial nerve graft cohort.
Potential prognostic factors for facial nerve function such as age, gender, extent of surgery at the time of nerve grafting, preoperative facial nerve palsy, duration of preoperative palsy if present, or number of previous operations in the parotid bed were relatively well balanced between irradiated and unirradiated patients. However, the irradiated graft group had a greater proportion of patients with pathologic evidence of nerve invasion (p = 0.007) and unfavorable type of nerve graft (p = 0.04). Although the irradiated graft cohort had more potentially negative prognostic factors, there was no difference in functional outcome (H-B Grade III or IV) between irradiated and unirradiated graft patients. H-B Grades III, IV, V, and VI were the best postoperative facial nerve functions achieved in 35%, 39%, 13%, and 13% of patients, respectively. The patient with preoperative radiotherapy never recovered any facial nerve function (H-B Grade VI). Median time to best facial nerve function after surgery was longer in the irradiated patients (13.1 vs. 10.8 months), but this was not statistically significant (p = 0.10). Presence of preoperative facial nerve palsy (p = 0.005), duration of preoperative palsy (p = 0.003), and age greater than 60 years at the time of grafting (p = 0. 04) were all negative prognostic factors for achieving a functional facial nerve on univariate analysis. Analysis of age as a continuous variable (p = 0.12) and pathologic evidence of nerve invasion (p = 0. 1) revealed a trend toward negative prognostic factors. Gender, number of previous operations in the parotid bed, extent of surgery at the time of nerve grafting, and type of grafting procedure were not significant prognostic factors. Whether radiotherapy was delivered less than 6 weeks after nerve grafting or more than 6 weeks had no impact on achievement of a functional facial nerve.
Negative prognostic factors for achieving a functional facial nerve in our series include the presence of preoperative facial nerve palsy, duration of preoperative palsy, and age greater than 60 years. Radiotherapy was not a negative prognostic factor. Comparing irradiated and unirradiated grafts revealed no difference in best facial nerve function achieved, despite the presence of a greater proportion of negative prognostic factors in
高剂量放射治疗对面神经移植的影响存在争议。一些作者认为放射治疗对移植面神经功能的结果极为不利,以至于对于所有接受术后放射治疗的患者,应采用动态或静态悬吊术而非面神经移植术。遗憾的是,动态和静态悬吊术所实现的面部功能几乎总是逊于面神经移植术后的功能。在这项回顾性研究中,我们对比了接受照射和未接受照射的移植面神经的功能。
回顾了1974年至1997年间接受治疗的818例腮腺肿瘤患者的病历,其中66例接受了面神经移植。排除了14例面神经移植术后不到一年死亡或复发的患者。其余52例患者的中位随访时间为10.6年。50例患者进行了电缆神经移植,2例进行了面神经直接吻合。采用House - Brackmann(H - B)面部分级系统对面神经功能进行评分。52例患者中有28例接受了术后放疗。从神经移植到开始放疗的中位时间为5.1周。接受照射的移植神经的中位和平均放射剂量分别为6000 cGy和6033 cGy。1例患者术前接受了总量为5000 cGy、分25次的放疗,并在放疗结束后1个月接受了手术。按照惯例,该患者被归入接受照射的移植面神经队列。
面神经功能的潜在预后因素,如年龄、性别、神经移植时的手术范围、术前面神经麻痹、若存在术前麻痹的持续时间或腮腺床既往手术次数,在接受照射和未接受照射的患者之间相对平衡。然而,接受照射的移植组中神经侵犯病理证据的患者比例更高(p = 0.007),且移植神经类型不佳(p = 0.04)。尽管接受照射的移植队列有更多潜在的负面预后因素,但接受照射和未接受照射的移植患者在功能结局(H - B III级或IV级)上并无差异。H - B III级、IV级、V级和VI级分别是35%、(39%)、13%和13%的患者术后实现的最佳面神经功能。接受术前放疗的患者未恢复任何面神经功能(H - B VI级)。照射组患者术后达到最佳面神经功能的中位时间更长(13.1个月对10.8个月),但这无统计学意义(p = 0.10)。单因素分析显示,术前面神经麻痹(p = 0.005)、术前麻痹持续时间(p = 0.003)以及移植时年龄大于60岁(p = 0.04)均是实现功能性面神经的负面预后因素。将年龄作为连续变量分析(p = 0.12)以及神经侵犯病理证据分析(p = 0.1)显示有负面预后因素的趋势。性别、腮腺床既往手术次数、神经移植时的手术范围以及移植手术类型均不是显著的预后因素。神经移植后6周内或6周后进行放疗对实现功能性面神经并无影响。
在我们的系列研究中,实现功能性面神经的负面预后因素包括术前面神经麻痹的存在、术前麻痹的持续时间以及年龄大于60岁。放射治疗不是负面预后因素。对比接受照射和未接受照射移植神经发现,尽管接受照射组负面预后因素比例更高,但在实现的最佳面神经功能方面并无差异。